Britain’s GSK and France’s Sanofi on Monday stated that they had began a brand new scientific trial of their protein-based COVID-19 vaccine candidate and purpose to achieve the ultimate testing stage within the second quarter.

If the outcomes are conclusive, the 2 drug makers hope to see the vaccine permitted by the fourth quarter after having initially focused the primary half of this yr.

The transfer comes after the drug makers in December stated their vaccine can be delayed after scientific trials confirmed an inadequate immune response in older folks.

The brand new trial will purpose at evaluating the protection, tolerability, and immune response of the vaccine in 720 wholesome adults throughout america, Honduras, and Panama, the businesses stated.

Sanofi and GSK’s candidate makes use of the identical recombinant protein-based expertise as considered one of Sanofi’s seasonal influenza vaccines. It will likely be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

The research will check two injections given 21 days aside.